This is the vaccine we're talking about. It's based on a messenger RNA (mRNA) that is stabilized by changing some of the nucleosides - the building blocks of the RNA - so that the mRNA is not broken down by the body too quickly. This mRNA encodes the spike protein of the SARS-CoV-2 virus, the most immunogenic part of the virus. It's this spike protein that allows the virus to enter a cell by binding to the ACE2 receptor. Subsequently, this mRNA is introduced into (muscle) cells via small particles, which then express the mRNA, and the 'spike protein' of the virus is placed on its own cell membrane, in the same way as it's on the membrane of the virus. There, it's recognized by the cells of the immune system and thus the immune response is triggered. This vaccination technique is new and has never been used before.
The 'Conclusions' section of the abstract of the paper reads: "A two dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines." This means that we simply don't know anything about the safety of this vaccine over a period of more than two months. That data simply isn't available.
But that's not all. The introduction of the article states that collecting data from the phase 2/3 studies that deal with the 'immunogenicity' and 'durabilitity' of the immune response - the degree to which the vaccine is able to elicit an immune response and how long this immune response lasts - is still ongoing and not reported in the article. Loosely translated, this means that it's not known whether the vaccine is able to induce a permanent immune response, which would permanently protect the recipient against infection with the SARS-CoV-2 virus...<<<Read The Full Article Here>>>...
